Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4T: Quadruple Therapy in Prediabetes and Obesity
NCT04131582Phase 3Unknown
- Sponsor
- Universidad de Guanajuato
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin and linagliptin in prediabetes (2 arms), sponsored by Universidad de Guanajuato. Primary endpoints: Change from basal fasting glucose at 12 months and Change from basal post-2h Oral Glucose Tolerance Test glucose at 12 months. Status: unknown.
02
Drugs
empagliflozinlinagliptin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT04131582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131582.